Elicio Therapeutics, Inc. (ELTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. on June 24, 2026. The Company is a biopharmaceutical entity focused on oncology, specifically reporting on its clinical development program for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing discloses a non-financial event: the hosting of a virtual key opinion leader (KOL) event on June 24, 2026.
Outlook, Commentary, and Risks
- Event Details: The Company hosted a virtual event featuring KOLs Zev Wainberg, M.D. (UCLA) and Peter Hosein, M.D. (University of Miami) to discuss the path forward for ELI-002 7P.
- Management Commentary: The presentation is included as Exhibit 99.1. The Company explicitly states it undertakes no obligation to update, supplement, or amend the material attached as Exhibit 99.1.
- Legal Status: The information under Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section.
Key Facts for Investor Verification
- Verify the clinical data and strategic roadmap for ELI-002 7P presented in Exhibit 99.1.
- Confirm the Company's current cash runway and funding status, as this 8-K does not disclose liquidity metrics.
- Monitor future filings for updates on the ELI-002 7P program, given the Company's disclaimer regarding updates to the presentation material.